IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, Christopher T. Ritchlin, María T. Abreu, M. Merle Elloso, Anne M. Fourie, Steven Fakharzadeh, Jonathan Sherlock, Ya‐Wen Yang, Daniel J. Cua, Iain B. McInnes
Abstract
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.